Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers
|
By LabMedica International staff writers Posted on 02 Aug 2018 |

Image: The Biolumi 8000 integrated system (Photo courtesy of Snibe).
Snibe Diagnostic (ShenZhen, China), a leading provider of chemiluminescence immunoassay solutions, presented its range of instruments at the 70th AACC (Annual Scientific Meeting & Clinical Lab Expo), which took place in Chicago, Illinois, USA, from Jul. 29 to Aug. 2, 2018.
Snibe is a professional bio-medical company that specializes in the research, production and sale of clinical laboratory instruments and in vitro diagnostic reagents. It is the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay product. The range of instruments presented by Snibe at this year’s AACC included the Biolumi 8000 integrated system, MAGLUMI 800 and MAGLUMI 2000 chemiluminiscence immunoassay systems and the Biossays 240 biochemistry analyzer.
The Biolumi 8000 integrated system combines an electrolyte module, chemistry module and immunoassay module in a single platform. Tests run on the system provide physicians with a wide range of assays, including 121 immunoassay, 47 chemistry, and four electrolyte assays. The Maglumi 800 chemiluminiscence immunoassay system features three modes of operation, sample loading for up to 40 sample tubes, continuous loading, STAT available, and LIS connection. The system offers a wide test menu, with a throughput of up to 180 tests per hour and the first results available in only 17 minutes. The MAGLUMI 2000 chemiluminiscence immunoassay system has a throughput of up to 180 tests/hour with time to first results of 17 minutes and is always ready-to-use. The Biossays 240 biochemistry analyzer has a throughput of constant 240 tests/hour and allows up to 90 sample positions to be loaded continuously on sample disk with barcode recognition.
Snibe is a professional bio-medical company that specializes in the research, production and sale of clinical laboratory instruments and in vitro diagnostic reagents. It is the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay product. The range of instruments presented by Snibe at this year’s AACC included the Biolumi 8000 integrated system, MAGLUMI 800 and MAGLUMI 2000 chemiluminiscence immunoassay systems and the Biossays 240 biochemistry analyzer.
The Biolumi 8000 integrated system combines an electrolyte module, chemistry module and immunoassay module in a single platform. Tests run on the system provide physicians with a wide range of assays, including 121 immunoassay, 47 chemistry, and four electrolyte assays. The Maglumi 800 chemiluminiscence immunoassay system features three modes of operation, sample loading for up to 40 sample tubes, continuous loading, STAT available, and LIS connection. The system offers a wide test menu, with a throughput of up to 180 tests per hour and the first results available in only 17 minutes. The MAGLUMI 2000 chemiluminiscence immunoassay system has a throughput of up to 180 tests/hour with time to first results of 17 minutes and is always ready-to-use. The Biossays 240 biochemistry analyzer has a throughput of constant 240 tests/hour and allows up to 90 sample positions to be loaded continuously on sample disk with barcode recognition.
Latest AACC 2018 News
- Mesa Biotech Showcases PCR Testing Platform at Clinical Expo
- Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018
- Abbott Diagnostics Displays Alinity Family of Systems
- Roche Diagnostics Highlights Latest Clinical Lab Solutions at AACC
- Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology
- Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show
- Thermo Fisher Scientific Showcases Product Portfolio at Lab Trade Show
- EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018
- Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo
- Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio
- Beckman Coulter Features New Hematology Analyzers and Lab Automation
- Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers
- Orion Diagnostica Showcases Rapid Test and Molecular Platform at Lab Show
- Saladax Biomedical Launches Game-Changing Assays at AACC 2018
- SeraCare Life Sciences Promotes New AccuSpan Panel at Lab Expo
- Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers
Channels
Clinical Chemistry
view channel
POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
Pseudomonas aeruginosa is a major cause of hospital-acquired and ventilator-associated pneumonia, particularly in lung transplant recipients and patients with structural lung disease. Its ability to form... Read more
Online Tool Detects Drug Exposure Directly from Patient Samples
Doctors often rely on patient interviews and medical records to determine what medications a person has taken, but this information is frequently incomplete. People may forget drugs they used, take over-the-counter... Read moreMolecular Diagnostics
view channel
Blood Biomarker Improves Early Brain Injury Prognosis After Cardiac Arrest
After a cardiac arrest, many patients remain unconscious for days, leaving doctors and families facing uncertainty about whether meaningful recovery is possible. Current tools to assess brain damage, including... Read more
Biomarkers Could Identify Patients at High Risk of Severe AKI After Major Surgery
Acute kidney injury is one of the most common and dangerous complications after major surgery, particularly among patients in intensive care. Even mild impairment of kidney function can lead to long-term... Read more
CLIA Test Identifies Head and Neck Cancer Recurrence from Post-Surgical Lymphatic Fluid
While the lymphatic system’s critical role in metastasis has long been recognized, routine access to patient lymph has been elusive. Now, a non-invasive process can access lymph through the collection... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channelBlood Test Could Detect Adverse Immunotherapy Effects
Immune checkpoint inhibitors have transformed cancer treatment, but they can also trigger serious immune-related adverse events that damage healthy organs and may become life-threatening if not detected early.... Read more
Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read moreMicrobiology
view channel
Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
Lower-respiratory tract infections (LRTIs) are a leading cause of illness and death worldwide, and pneumonia is the leading infectious cause of death in children under five, claiming the lives of over... Read more
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more
Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease
Blood-based tests for Alzheimer’s disease are transforming diagnosis by offering a simpler alternative to spinal taps and brain imaging. However, many people evaluated at memory clinics also live with... Read more
Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk
Chronic liver disease affects millions worldwide and can progress silently to hepatocellular carcinoma (HCC), one of the deadliest cancers globally. While surveillance guidelines exist for patients with... Read moreTechnology
view channel
Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that is notoriously difficult to diagnose in its early stages. Early symptoms often overlap with other neurological... Read more
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read moreIndustry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more









